Group 1 - The core point of the news is that BaiO Saite's stock price dropped by 5% to 71.82 yuan per share, with a trading volume of 1.32 billion yuan and a turnover rate of 5.00%, resulting in a total market capitalization of 32.096 billion yuan [1] - BaiO Saite (Beijing) Pharmaceutical Technology Co., Ltd. is primarily engaged in antibody drug research and preclinical research services, with operations divided into five segments, including gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development focusing on oncology and autoimmune diseases [1] Group 2 - According to data from the top ten holdings of funds, Penghua Fund holds BaiO Saite in its portfolio, specifically in the Penghua New Emerging Industries Mixed A Fund (206009), which held 2.307 million shares, accounting for 3.77% of the fund's net value, ranking as the tenth largest holding [2] - The Penghua New Emerging Industries Mixed A Fund has a total scale of 3.215 billion yuan, with a year-to-date return of 9.29% and a one-year return of 49.94%, ranking 1661 out of 8994 and 1568 out of 8199 respectively [2]

Group 1 - The core viewpoint of the news is that BaiO Technology has seen a significant increase in its stock price, rising by 5.02% to 75.25 CNY per share, with a total market capitalization of 33.629 billion CNY [1] - BaiO Technology, established on November 13, 2009, specializes in antibody drug research and preclinical research services, operating five divisions including gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development focused on oncology and autoimmune diseases [1] - The company is located in the Daxing District of Beijing, within the Zhongguancun Science Park, and is set to be listed on December 10, 2025 [1] Group 2 - According to data, a fund under Bank of China Securities holds a significant position in BaiO Technology, with the Bank of China Health Industry Mixed Fund (002938) owning 90,000 shares, representing 3.82% of the fund's net value, making it the seventh-largest holding [2] - The Bank of China Health Industry Mixed Fund was established on September 7, 2016, with a current scale of 124 million CNY, and has experienced a year-to-date loss of 0.49% [2] - The fund has achieved a one-year return of 24.49% and a cumulative return of 114.52% since its inception, ranking 4485 out of 8127 in its category [2]

Group 1 - On January 12, BaiOsaite's stock increased by 14.87%, with a trading volume of 425 million yuan [1] - The financing data shows that BaiOsaite had a financing purchase amount of 27.33 million yuan and a financing repayment of 27.84 million yuan, resulting in a net financing buy of -0.51 million yuan [1] - As of January 12, the total balance of BaiOsaite's margin trading was 55.79 million yuan, which accounts for 2.26% of its circulating market value [1] Group 2 - BaiOsaite (Beijing) Pharmaceutical Technology Co., Ltd. was established on November 13, 2009, and is located in the Daxing District of Beijing [2] - The company specializes in antibody drug research and preclinical research services, operating five divisions [2] - The divisions include gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development focused on oncology and autoimmune diseases [2]

1月5日，百奥赛图涨4.66%，成交额3.51亿元。两融数据显示，当日百奥赛图获融资买入额3423.52万 元，融资偿还3584.56万元，融资净买入-161.05万元。截至1月5日，百奥赛图融资融券余额合计5748.52 万元。 融资方面，百奥赛图当日融资买入3423.52万元。当前融资余额5748.52万元，占流通市值的2.91%。 资料显示，百奥赛图(北京)医药科技股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业 基地宝参南街12号院，成立日期2009年11月13日，上市日期2025年12月10日，公司主营业务涉及百奥赛 图（北京）医药科技股份有限公司是一家主要提供抗体药物研发和临床前研究服务的中国公司。该公司 运营五个分部。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分 部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动 物，亦向客户授出若干模式动物的许可。抗体开发分部识别有潜力成为候选药物的抗体，并就潜在治疗 性抗体分子对外授权或与合作伙伴合作。创新药开发分部研发创新药，专注肿瘤学和自身免疫性疾病治 疗。 责任编辑：小浪 ...

Group 1 - On December 22, Bai'ao Saitou's stock increased by 3.14%, with a trading volume of 304 million yuan [1] - The financing data shows that on the same day, Bai'ao Saitou had a financing purchase amount of 35.87 million yuan and a net financing purchase of 14.28 million yuan [1] - As of December 22, the total balance of Bai'ao Saitou's margin trading was 109 million yuan, accounting for 5.88% of its market capitalization [1] Group 2 - Bai'ao Saitou (Beijing) Pharmaceutical Technology Co., Ltd. was established on November 13, 2009, and is located in the Daxing District of Beijing [2] - The company specializes in antibody drug research and preclinical research services, operating five divisions including gene editing services and preclinical pharmacology evaluation [2] - The innovative drug development division focuses on developing new drugs for oncology and autoimmune diseases [2]

Group 1 - The core viewpoint of the news is that BaiO Technology's stock has experienced a decline of 22.28% this year and an 8.61% drop in the last five trading days, with current trading activity showing a slight increase in stock price [1] - BaiO Technology is a Chinese company primarily engaged in antibody drug research and preclinical research services, established on November 13, 2009, and listed on December 10, 2025 [2] - The company operates five divisions, including gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development focused on oncology and autoimmune diseases [2] Group 2 - BaiO Technology is categorized under the pharmaceutical and biological industry, specifically in medical services and medical research outsourcing [2] - The company is associated with several concept sectors, including cell therapy, innovative drugs, pre-profit and profit growth, newly listed stocks, and specialized and innovative enterprises [2]

Group 1 - The core viewpoint of the news is that BaiO Technology's stock has experienced a significant decline this year, with a drop of 21.72% and a recent 5-day decline of 11.54% [1] - As of December 19, BaiO Technology's stock price was 51.51 CNY per share, with a market capitalization of 23.02 billion CNY [1] - The company experienced a net outflow of main funds amounting to 6.38 million CNY, with large orders showing a buy of 22.73 million CNY and a sell of 28.98 million CNY [1] Group 2 - BaiO Technology, established on November 13, 2009, is located in the Daxing District of Beijing and specializes in antibody drug research and preclinical research services [2] - The company operates five divisions, including gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development focusing on oncology and autoimmune diseases [2] - BaiO Technology is categorized under the pharmaceutical and biological industry, specifically in medical services and medical research outsourcing, with concepts including innovative drugs, cell therapy, and CRO [2]

融券方面，百奥赛图12月18日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元。 12月18日，百奥赛图涨0.40%，成交额3.15亿元。两融数据显示，当日百奥赛图获融资买入额2735.36万 元，融资偿还2398.44万元，融资净买入336.92万元。截至12月18日，百奥赛图融资融券余额合计 9173.00万元。 融资方面，百奥赛图当日融资买入2735.36万元。当前融资余额9173.00万元，占流通市值的5.07%。 资料显示，百奥赛图(北京)医药科技股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业 基地宝参南街12号院，成立日期2009年11月13日，上市日期2025年12月10日，公司主营业务涉及百奥赛 图（北京）医药科技股份有限公司是一家主要提供抗体药物研发和临床前研究服务的中国公司。该公司 运营五个分部。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分 部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动 物，亦向客户授出若干模式动物的许可。抗体开发分 ...